Nikolai Siebert Selected Research

dinutuximab

1/2022	First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma.
1/2021	Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
10/2020	Reduction of CD11b+ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody ch14.18/CHO.
5/2020	GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.
1/2020	Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma.
1/2020	Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy.
1/2019	Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.
10/2018	Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.
1/2018	Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.
1/2018	Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nikolai Siebert Research Topics

Disease

19	Neuroblastoma 01/2021 - 06/2013
11	Neoplasms (Cancer) 01/2022 - 06/2013
2	Ewing Sarcoma (Sarcoma, Ewing) 01/2022 - 01/2019
2	Neoplasm Metastasis (Metastasis) 10/2019 - 01/2018
2	Pain (Aches) 10/2018 - 01/2018
2	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2018 - 01/2016
2	Acute Liver Failure (Fulminant Hepatic Failure) 05/2009 - 12/2008
1	Sarcoma (Soft Tissue Sarcoma) 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2022
1	Glioma (Gliomas) 05/2020
1	Hodgkin Disease (Hodgkin's Disease) 01/2020
1	Melanoma (Melanoma, Malignant) 01/2020
1	Pathologic Complete Response 01/2020
1	Hemorrhage 08/2019
1	Liver Cirrhosis (Hepatic Cirrhosis) 10/2010
1	Necrosis 10/2010
1	Infarction (Infarctions) 10/2010
1	Hepatitis 10/2010
1	Infections 05/2009
1	Liver Failure 05/2009
1	Experimental Arthritis 01/2009
1	Arthritis (Polyarthritis) 01/2009
1	Rheumatoid Arthritis 01/2009
1	Hypersensitivity (Allergy) 01/2009
1	Liver Diseases (Liver Disease) 12/2008

Drug/Important Bio-Agent (IBA)

16	dinutuximabIBA 01/2022 - 12/2013
6	Interleukin-2 (IL2)IBA 01/2021 - 01/2016
5	CytokinesIBA 01/2018 - 12/2008
3	AntigensIBA 01/2022 - 06/2013
3	Proteins (Proteins, Gene)FDA Link 05/2020 - 05/2009
2	Chimeric Antigen ReceptorsIBA 01/2022 - 01/2019
2	Complement System Proteins (Complement)IBA 01/2021 - 05/2020
2	Morphine (MS Contin)FDA LinkGeneric 10/2018 - 01/2018
2	ganglidiomabIBA 12/2013 - 06/2013
2	CollagenIBA 10/2010 - 01/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2009 - 12/2008
1	Interleukin-4 (Interleukin 4)IBA 10/2020
1	Fluorouracil (Carac)FDA LinkGeneric 10/2020
1	Interleukin-8 (Interleukin 8)IBA 10/2020
1	NivolumabIBA 01/2020
1	Blood Coagulation Factors (Coagulation Factor)IBA 08/2019
1	EnzymesIBA 01/2019
1	Enhancer of Zeste Homolog 2 ProteinIBA 01/2019
1	Surface Antigens (Surface Antigen)IBA 01/2019
1	GD2 gangliosideIBA 01/2019
1	Interleukin-15 (Interleukin 15)IBA 01/2018
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2018
1	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 01/2018
1	VaccinesIBA 01/2018
1	DNA (Deoxyribonucleic Acid)IBA 01/2018
1	DNA VaccinesIBA 01/2018
1	LigandsIBA 01/2017
1	Immunoglobulin G (IgG)IBA 01/2016
1	Pharmaceutical PreparationsIBA 05/2015
1	Monoclonal AntibodiesIBA 12/2013
1	AntibodiesIBA 06/2013
1	Erythropoietin FDA Link 10/2010
1	LipopolysaccharidesIBA 05/2009
1	Transaminases (Aminotransferases)IBA 05/2009
1	Granzymes (Granzyme)IBA 05/2009
1	PerforinIBA 05/2009
1	GalactosamineIBA 05/2009
1	Phosphatidylcholines (Phosphatidylcholine)IBA 01/2009
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2009

Therapy/Procedure

11	Immunotherapy 01/2022 - 06/2013
4	Therapeutics 01/2022 - 01/2009
1	Consolidation Chemotherapy 01/2022
1	Stem Cell Transplantation 01/2021
1	Hematopoietic Stem Cell Transplantation 01/2021
1	Regimen B 01/2020
1	Neurosurgical Procedures 10/2019
1	Enterostomy 08/2019
1	Surgical Decompression 08/2019